A
Amitabha Bhaumik
Researcher at Bristol-Myers Squibb
Publications - 12
Citations - 129
Amitabha Bhaumik is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 4, co-authored 4 publications receiving 118 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension.
Joel M. Neutel,Stanley S. Franklin,Suzanne Oparil,Amitabha Bhaumik,Agata Ptaszynska,Pablo Lapuerta +5 more
TL;DR: Greater and more rapid BP reduction with irbesartan/HCTZ was achieved without additional side effects, and the mean difference between combination and monotherapy in seated diastolic BP and seated systolic BP was 4.7 mm Hg.
Journal ArticleDOI
A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension.
TL;DR: In conclusion, irbesartan/HCTZ (300/25 mg) is well tolerated and achieves rapid and sustained reductions in both systolic blood pressure and diastolicBlood pressure in patients with moderate hypertension.
Journal ArticleDOI
The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk
TL;DR: Irbesartan/HCTZ provided consistent blood pressure lowering and tolerability regardless of age, obesity, and type 2 diabetes and greater efficacy in patients with high cardiovascular risk.
Journal ArticleDOI
Safety and Tolerability of Fixed-Dose Irbesartan/Hydrochlorothiazide for Rapid Control of Severe Hypertension
TL;DR: Despite more rapid and aggressive BP lowering, initial fixed-dose irbesartan/HCTZ demonstrated a comparable AE profile to irbesARTan monotherapy in patients with severe hypertension.
Journal ArticleDOI
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.
Subhra Chowdhury,Anders Bjartell,Nikita Agarwal,B. H. Chung,Robert Given,Andrea J. Pereira de Santana Gomes,Alex S. Merseburger,M. Özgüroĝlu,Álvaro Juárez Soto,Hirotugu Uemura,D. Ye,Sabine Brookman-May,Anil Londhe,Amitabha Bhaumik,Suneel D. Mundle,Julie S. Larsen,Sharon Anne McCarthy,Kim N. Chi +17 more
TL;DR: The first interim analysis of the phase III, randomized, double-blind, placebo-controlled, multinational TITAN study demonstrated improved overall survival (OS) and radiographic progression-free survival (rPFS) with apalutamide added to ongoing androgen deprivation therapy (ADT) in patients with metastatic castration-sensitive prostate cancer as mentioned in this paper .